文献速递中医内科中医康复中药与中成药合理使用

补肺活血胶囊治疗COVID-19恢复期患者的多中心随机双盲对照试验

Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial.
PubMed 文献 · J Ethnopharmacol · 2021-11-09

本研究为多中心、双盲、随机对照试验,纳入131例COVID-19恢复期患者,随机分为补肺活血胶囊组(n=66)和安慰剂组(n=65),口服给药每日三次(每次1.4g)共90天。结果显示补肺活血胶囊在减轻胸部CT肺炎病灶、改善6分钟步行距离和疲劳评分方面均优于安慰剂,不良反应发生率组间无显著差异。

要点

  • 补肺活血胶囊可减轻COVID-19恢复期患者胸部CT肺炎病灶。
  • 补肺活血胶囊改善6分钟步行距离和疲劳评分优于安慰剂。
  • 不良反应发生率组间无显著差异,安全性可接受。

核心结论

  • 补肺活血胶囊可能对COVID-19恢复期患者产生较强的康复效果,减轻疲劳症状并改善运动耐量。

研究设计与样本

  • 多中心、双盲、随机对照试验,共纳入131例COVID-19恢复期患者,随机分为补肺活血胶囊组(n=66)和安慰剂组(n=65)。
  • 补肺活血胶囊或安慰剂口服,每日三次,每次1.4g,疗程90天。
  • 排除2例未接受任何药物即退出的患者后,实际分析129例(补肺活血胶囊组64例,安慰剂组65例)。

主要发现

  • 治疗3个月后,补肺活血胶囊组胸部CT肺炎病灶减轻程度优于安慰剂组(P<0.05)。
  • 补肺活血胶囊组6分钟步行距离较基线的改善显著优于安慰剂组(P<0.01)。
  • 补肺活血胶囊组疲劳评定量表评分低于安慰剂组(P<0.05)。
  • 补肺活血胶囊组不良事件发生率为9.38%,安慰剂组为4.62%,差异无统计学意义(P=0.3241)。

临床怎么用

  • 对于COVID-19恢复期存在肺炎病灶、运动耐量下降或疲劳的患者,可考虑在评估后使用补肺活血胶囊进行康复治疗。
  • 使用期间需关注不良事件,尽管本研究中组间差异无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As of September 17, 2021, coronavirus disease 2019 (COVID-19) has infected more than 226 million people in a worldwide pandemic, with conservative estimates suggesting that there are more than 204 million convalescent patients with COVID-19. Previous studies have indicated that patients in the recovery phase exhibit decreased function of multiple organs. In China, traditional Chinese medicine (TCM) treatment is recommended in the rehabilitation period of COVID-19; however, the safety and efficacy of such treatment remain to be confirmed. AIM OF STUDY: The present study aimed to evaluate the efficacy and safety of Bufei Huoxue (BFHX) in restoring the functional status and exercise tolerance of patients recovering from COVID-19. METHODS: A total of 131 patients in the rehabilitation period of COVID-19 infection were randomly divided into a Bufei Huoxue (BFHX) group (n = 66) and a placebo group (n = 65). BFHX or placebo was given orally three times a day (1.4 g/dose) for 90 days. The primary outcomes was to evaluate improvements in exercise tolerance and imaging manifestations on chest computed tomography (CT). RESULTS: After the exclusion of two patients who withdrew prior to receiving any medications, 129 patients were recruited, including 64 patients in the BFHX group and 65 patients in the placebo group. After 3 months of treatment, the BFHX group exhibited greater attenuation of pneumonia lesions on chest CT than the placebo group (P<0.05). Improvements in 6-min walk distance (6MWD) relative to baseline were also significantly better in the BFHX group than in the placebo group (P<0.01). Scores on the Fatigue Assessment Inventory (FAI) were lower in the BFHX group than in the placebo group (P<0.05). Although the rate of adverse events was higher in the BFHX group than in the placebo group (9.38% vs. 4.62%), the difference was not significant (P=0.3241). CONCLUSIONS: BFHX may exert strong rehabilitative effects on physiological activity in patients recovering from COVID-19, which may in turn attenuate symptoms of fatigue and improve exercise tolerance.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Liu C, Wang T, et al. Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial. J Ethnopharmacol. 2021. PMID: 34763045. doi:10.1016/j.jep.2021.114830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。